Anti‐inflammatory and remyelinating effects of fexagratinib in experimental multiple sclerosis
Multi-kinase inhibition by fexagratinib in a well-tolerated dose of 1 mg·kg<sup>-1</sup> in humans may be a promising approach to reduce inflammation and neurodegeneration, to slow down disease progression and support remyelination in patients.
Authors
- Gregor Böttiger (ORCID: https://orcid.org/0000-0002-2557-3302)
- Süleyman Ergün
- Christine Stadelmann (ORCID: https://orcid.org/0000-0003-1766-5458)
- Fevronia‐Foivi Megalofonou
- Sudhanshu Bhushan (ORCID: https://orcid.org/0000-0002-9088-8108)
- Fynn Gurski
- Martin Berghoff (ORCID: https://orcid.org/0000-0001-7954-3646)
- Srikanth Karnati (ORCID: https://orcid.org/0000-0001-9083-2916)
- Vinothkumar Rajendran (ORCID: https://orcid.org/0000-0001-9425-8579)
- R. Rajendran (ORCID: https://orcid.org/0000-0003-0487-7347)
- Kian Shirvanchi (ORCID: https://orcid.org/0000-0002-8297-3855)
Institutions
- Justus-Liebig-Universität Gießen (DE)
- University of Würzburg (DE)
- Giessen School of Theology (DE)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2024-10-05
- DOI
- https://doi.org/10.1111/bph.17341
- Citations
- 4
- Primary Topic
- Protein Tyrosine Phosphatases
- Type
- article
- Field-Weighted Citation Impact
- 0.94